Is Healthy Life overvalued or undervalued?

As of 26 September 2025, Healthy Life's valuation grade has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued. Key ratios include a PE ratio of 35.28, an EV to EBITDA of 25.01, and a ROCE of 11.36%.
In comparison to its peers, Healthy Life's PE ratio is notably lower than Hindustan Unilever's 55.46 and Nestle India's 74.54, both of which are categorized as very expensive. This suggests that Healthy Life presents a more favorable investment opportunity relative to these competitors. Despite recent stock performance showing a decline against the Sensex, with a YTD return of -71.93% compared to the Sensex's 2.93%, the current valuation metrics indicate that Healthy Life is positioned for potential recovery and growth in the future.